Treatment Phase Sample Clauses

Treatment Phase. As regards a Scheme Participant who has undergone and completed the Screening Phase, the same Private Doctor may admit the Scheme Participant to the Treatment Phase under his care and the Private Doctor shall:
Sample 1Sample 2
AutoNDA by SimpleDocs
Treatment Phase. 8 A. Procedure ..........................................................................................9 V. Data Analvsis .............................................................................................9 VI . Background..............................................................................................9 ................
Sample 1
Treatment Phase. In the TREATMENT phase – 60 DAYS - the heart of DOREMI, Participants will maintain a personalized plan, the support of videos and exergames but the role of the Coaching will be limited and on demand. Controls will have ADL as usual; Control and Participants will be monitored by WSN and Bracelet. The final aim of DOREMI PA TREATMENT protocol will be: - the empowerment of ADL (increase of physical activity level as described in §6.1.6) with the acquisition of simple elements related to the specific physical activity according to personalized pathologies, physical limits and status; - the verification of the effect of the physical activity in the treatment time; - the engagement of the Users through appropriate stimulation and game-based motivations which will support his behavioural changes in the adherence of better lifestyle management protocols; - the evaluation of educational intervention for improving movement and lifestyle behaviour in the Elderly on metabolic and physiological functions plus cognitive/psychological functions; - the compliance to methodologies and results obtained to set improved ICT/technologies/ instrument calibrated for our Users.
Sample 1
Treatment Phase. Treatment activities of PARTICIPANTS Participants will: Treatment activities of CONTROLS Controls will:
Sample 1
Treatment Phase. Started from day 26, PARTICIPANTS will be requested to follow the DOREMI Cognitive Protocol every day within the timeframe necessary to carry out and complete the daily tasks (to be decided in the next days, depending on the number of proposed games). Indicatively, no strict rules are previewed concerning the timeframe; the only requirement is the task completion day by day. Regarding the games library, users will follow their specific game plan, as explained in the previous paragraph. Users are supposed to play autonomously, possibly deciding whether to involve other participants (cooperation/competition). The presence of the staff member will be assured every 2 weeks for support. The only exceptions will be due to one of these conditions: if requested by the subject, bad functioning of the device, reiterated failure in the tasks completion. Distance monitoring and collection of data will be constantly assured by the software developed by XXXXXX. During the first 3 days of the treatment phase, the approach to games will be gradual, whereas from the fourth day on, the proper Cognitive protocol will start.  The first approach to games is free, in order to newly enhance familiarization with the platform.  Provision of the range of games, with a complexity level complying with the functional class defined though the overall score of the cognitive tests, A, B or C.  Complexity levels will be attuned with the score achieved on the previous day
Sample 1
Treatment Phase. On treatment day, subjects will have their wound debrided as necessary, photographed, assessed using the E-Z Graph Wound Assessment System and treated using MIRODERM. They will be asked to return weekly for dressing and wound assessment. After treatment with MIRODERM, subjects will be considered enrolled into the trial. Details of treatment will be documented. Weekly, for up to 12 weeks, subjects will return, have their wound assessed for closure. As clinically appropriate, they may have their wound debrided and treated using MIRODERM. The wound will be photographed and assessed using the E-Z Graph Wound Assessment System and treatment details will be documented as applicable. The subject will receive a $25 gift card for attending the follow-up visit. If wound has not closed, the dressing will be changed (subsequent to any needed treatment as described in the above paragraph) and the subject will return the following week. If the wound is healed subject will return for a confirmation visit one week later. If, after 12 weeks, the wound is not healed, subject will complete a SF-36 quality of life survey, two tissue sections of at least 2mm from the wound area will be collected and the subject will be discontinued from the study per protocol.
Sample 1

Related to Treatment Phase

  • Treatment The Asset Representations Reviewer agrees to hold and treat Confidential Information given to it under this Agreement in confidence and under the terms and conditions of this Section 4.08, and will implement and maintain safeguards to further assure the confidentiality of the Confidential Information. The Confidential Information will not, without the prior consent of the Issuer and the Servicer, be disclosed or used by the Asset Representations Reviewer, or its officers, directors, employees, agents, representatives or affiliates, including legal counsel (collectively, the “Information Recipients”) other than for the purposes of performing Reviews of Review Receivables or performing its obligations under this Agreement. The Asset Representations Reviewer agrees that it will not, and will cause its Affiliates to not (i) purchase or sell securities issued by the Seller or its Affiliates or special purpose entities on the basis of Confidential Information or (ii) use the Confidential Information for the preparation of research reports, newsletters or other publications or similar communications.

  • Treatment of Fees The fees described in this Section 5 (a) are not compensation for the use, detention, or forbearance of money, (b) are in addition to, and not in lieu of, interest and expenses otherwise described in this Agreement, (c) are payable in accordance with Section 3.1(c), (d) are non-refundable, and (e) to the fullest extent permitted by Law, bear interest, if not paid when due, at the Default Rate.

  • Future Treatment of Unallowable Costs Unallowable Costs shall be separately determined and accounted for by Defendants, and Defendants shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Defendants or any of their subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.

  • Emergency Medical Treatment I grant the Releasees permission to authorize emergency medical treatment as they deem appropriate, and agree that such action by the Releasees shall be subject to the terms of this Agreement. I understand and agree that the Releasees assume no responsibility for any injury or damage that might result from such emergency medical treatment.

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Treatment of Options (a) Upon and subject to the conditions set forth in this Agreement, immediately prior to the Effective Time, each option to purchase Company Common Stock then outstanding (each, a “Company Option”) to the extent then exercisable (after giving effect to any acceleration resulting from the transactions contemplated by this Agreement), at an exercise price per share less than the Merger Consideration (each such Company Option, a “Cashed Out Option”), shall entitle the holder thereof to receive from Parent as soon as practicable following the Effective Time, an amount in cash, without interest, equal to the product of (x) the total number of shares of Company Common Stock subject to such Company Option multiplied by (y) the excess of the amount of the Merger Consideration over the exercise price per share of Company Common Stock under such Company Option (with the aggregate amount of such payment rounded up to the nearest cent, less applicable taxes, if any, required by Applicable Law to be withheld by the Company or Merger Sub on behalf of such holder). (b) Upon and subject to the conditions set forth in this Agreement, at the Effective Time, each Company Option other than a Cashed Out Option, granted under any Company Stock Plan and outstanding immediately prior to the Effective Time shall be converted into an option to acquire such number of shares of Parent Common Stock (a “Converted Option”) equal to the product obtained by multiplying (x) the aggregate number of shares of Company Common Stock that were issuable upon exercise of such Converted Option immediately prior to the Effective Time and (y) the quotient obtained by dividing (1) the Merger Consideration by (2) the average of the closing prices of one (1) share of Parent Common Stock, as quoted on NASDAQ for the ten (10) consecutive trading days immediately preceding the Closing Date (the “Exchange Ratio”), rounded down to the nearest whole number of shares of Parent Common Stock. The terms and conditions of the Converted Option, including the vesting schedule thereof (except to the extent otherwise provided in any agreement between the Company and the holder of such Converted Option), shall otherwise remain the same as the terms and conditions of the Company Option, except that the exercise price per share of each Converted Option shall be equal to the quotient obtained by dividing (1) the exercise price per share of such Converted Option immediately prior to the Effective Time by (2) the Exchange Ratio, rounded up to the nearest whole cent. (c) On the Closing Date, Parent shall file a registration statement on Form S-3 or Form S-8, as the case may be (or any successor or other appropriate forms), with respect to the shares of Parent Common Stock subject to the Converted Options and shall use its commercially reasonable best efforts to maintain the effectiveness of such registration statement or registration statements (and maintain the current status of the prospectus or prospectuses contained therein) for so long as such Converted Options remain outstanding.

  • Treatment of Interest For Federal and State tax purposes (i) interest shall accrue at the Accrual Rate, and (ii) payments made pursuant to section 2 shall first be treated as interest, up to the amount of interest so accrued, then shall be treated as principal, until Purchaser has received, as principal, the entire Principal Amount, and then shall be treated as interest.

  • Vaccination and Inoculation ‌ (a) The Employer agrees to take all reasonable precautions to limit the spread of infectious diseases among employees, including in-service seminars for employees. Where the Employer or Occupational Health and Safety Committee identifies high risk areas which expose employees to infectious or communicable diseases for which there are protective immunizations available, such immunizations shall be provided at no cost to the employee. The Committee may consult with the Medical Health Officer. Where the Medical Health Officer identifies such a risk, the immunization shall also be provided at no cost. The Employer shall provide Hepatitis B vaccine, free of charge, to those employees who may be exposed to bodily fluids or other sources of infection. (b) An employee may be required by the Employer, at the request of and at the expense of the Employer, to take a medical examination by a physician of the employee's choice. Employees may be required to take skin tests, x-ray examination, vaccination, and other immunization (with the exception of a rubella vaccination when the employee is of the opinion that a pregnancy is possible), unless the employee's physician has advised in writing that such a procedure may have an adverse effect on the employee's health.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • Sale Treatment The Company has determined that the disposition of the Mortgage Loans pursuant to this Agreement will be afforded sale treatment for accounting and tax purposes;

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!